Studienzentrum an der Hase GbR
- Address
- Hasestr. 17, 49565 Bramsche, Germany
Studienzentrum an der Hase GbR - Dermatology Research Center
Studienzentrum an der Hase GbR is a specialized clinical research facility dedicated to advancing dermatological care through innovative therapeutic trials. The center focuses on evaluating novel treatment approaches for chronic inflammatory skin conditions, with particular expertise in conducting complex, multi-phase studies that assess both efficacy and safety profiles of emerging medications.
- Moderate to severe atopic dermatitis treatment studies
- Dose-ranging efficacy evaluations for novel dermatological agents
- Placebo- and active-controlled comparative trials
The research center specializes in Phase 2b clinical trials involving atopic dermatitis, a chronic inflammatory skin condition requiring careful long-term management. Their expertise encompasses sophisticated study designs including randomized, double-blind methodologies that evaluate investigational compounds against both placebo and established active treatments, ensuring robust data generation for regulatory submissions and advancing therapeutic options for patients with challenging dermatological conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Studienzentrum an der Hase GbR
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study) | Arctic Bioscience AS | Phase II | Not Recruiting | Mar 2023 | Mar 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apremilast | 1 | Unknown | 2025-01-16 | 2025-01-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.